Cancers, Vol. 13, Pages 4700: Vorinostat (SAHA) and Breast Cancer: An Overview
Cancers, Vol. 13, Pages 4700: Vorinostat (SAHA) and Breast Cancer: An Overview
Cancers doi: 10.3390/cancers13184700
Authors:
Anna Wawruszak
Lidia Borkiewicz
Estera Okon
Wirginia Kukula-Koch
Syeda Afshan
Marta Halasa
Vorinostat (SAHA), an inhibitor of class I and II of histone deacetylases, is the first histone deacetylase inhibitor (HDI) approved for the treatment of cutaneous T-cell lymphoma in 2006. HDIs are promising anticancer agents that inhibit the proliferation of many types of cancer cells including breast carcinoma (BC). BC is a heterogeneous disease with variable biological behavior, morphological features, and response to therapy. Although significant progress in the treatment of BC has been made, high toxicity to normal cells, serious side effects, and the occurrence of multi-drug resistance limit the effective therapy of BC patients. Therefore, new active agents which improve the effectiveness of currently used regimens are highly needed. This manuscript analyzes preclinical and clinical trials data of SAHA, applied individually or in combination with other anticancer agents, considering different histological subtypes of BC.
Source: Cancers - Category: Cancer & Oncology Authors: Anna Wawruszak Lidia Borkiewicz Estera Okon Wirginia Kukula-Koch Syeda Afshan Marta Halasa Tags: Review Source Type: research
More News: Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Clinical Trials | Cutaneous T cell lymphoma | Lymphoma | T-cell Lymphoma | Toxicology